Park Place Capital Corp Purchases 264 Shares of Novo Nordisk A/S $NVO

Park Place Capital Corp raised its position in Novo Nordisk A/S (NYSE:NVO) by 15.7% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,947 shares of the company’s stock after acquiring an additional 264 shares during the period. Park Place Capital Corp’s holdings in Novo Nordisk A/S were worth $136,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of NVO. Revolve Wealth Partners LLC lifted its stake in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Novo Nordisk A/S by 7,508.7% during the 1st quarter. GAMMA Investing LLC now owns 657,319 shares of the company’s stock worth $45,644,000 after purchasing an additional 648,680 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its position in shares of Novo Nordisk A/S by 34.2% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 4,179 shares of the company’s stock worth $290,000 after purchasing an additional 1,064 shares during the last quarter. Rhumbline Advisers increased its position in shares of Novo Nordisk A/S by 10.2% during the 1st quarter. Rhumbline Advisers now owns 63,539 shares of the company’s stock worth $4,412,000 after purchasing an additional 5,898 shares during the last quarter. Finally, 180 Wealth Advisors LLC increased its position in shares of Novo Nordisk A/S by 3.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company’s stock worth $348,000 after purchasing an additional 173 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.0%

Shares of Novo Nordisk A/S stock opened at $55.52 on Wednesday. The stock has a fifty day simple moving average of $55.62 and a 200 day simple moving average of $64.17. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $120.56. The company has a market capitalization of $247.90 billion, a P/E ratio of 15.25, a price-to-earnings-growth ratio of 2.10 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s payout ratio is currently 22.53%.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent analyst reports. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Morgan Stanley lowered Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and decreased their target price for the stock from $59.00 to $47.00 in a report on Monday. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Finally, TD Cowen decreased their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $75.33.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.